文献速递消化系统肿瘤

肝细胞癌的定制质子束治疗:多学科方法解决未满足需求

Tailored proton beam therapy for hepatocellular carcinoma: Addressing unmet needs through a multidisciplinary approach.
PubMed 文献 · Eur J Cancer · 2026-02-18

主要终点为局部无进展生存(FFLP),次要终点为总生存(OS)和毒性。结果显示2年FFLP在治疗各时间段均超过90%,不同BCLC分期的FFLP和OS存在显著差异,支持质子束治疗作为有前景的局部消融方式。

要点

  • 质子束治疗在不适合BCLC标准治疗的肝细胞癌患者中,2年局部无进展生存超过90%。
  • 不同BCLC分期的3年总生存率分别为81.1%(0期)、65.5%(A期)、45.5%(B期)和37.2%(C期)。
  • 质子束治疗可作为解决肝细胞癌未满足治疗需求的局部消融选择。

核心结论

  • 质子束治疗在不符合BCLC指南标准治疗的肝细胞癌患者中提供了良好的局部控制和生存结局。

主要发现

  • 所有病例中93.0%针对肝内病灶,7.0%针对肝外病灶。
  • 肝内病例中位随访19.5个月(IQR 8.5-39.7),各治疗时间段2年FFLP均超过90%(P=0.51)。
  • 按BCLC分期0、A、B、C,2年FFLP分别为95.5%、93.9%、98.5%、87.6%,3年FFLP分别为91.1%、91.3%、95.0%、83.3%(P<0.001)。
  • 中位OS随访18.7个月(IQR 7.9-38.6),3年OS率分别为81.1%(0期)、65.5%(A期)、45.5%(B期)、37.2%(C期)(P<0.001)。

临床怎么用

  • 对于不适合BCLC指南推荐标准治疗的肝细胞癌患者,质子束治疗可作为局部消融的替代选择。

局限性

  • 回顾性单中心研究设计可能引入选择偏倚。
  • 未报告毒性结局的具体数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since December 2015, the Proton Beam Therapy (PBT) center at Samsung Medical Center has treated 2000 cases involving 1823 patients with HCC who were ineligible for Barcelona Clinic Liver Cancer (BCLC) guideline-recommended standard treatments. This study evaluated clinical outcomes and explored the potential role of PBT as an alternative local modality. METHODS: We retrospectively reviewed patients with HCC treated with PBT. The primary endpoint was freedom from local progression (FFLP), and the secondary endpoints were overall survival (OS) and toxicity. RESULTS: The annual number of PBT cases increased, among all cases, 93.0 % targeted intrahepatic lesions, while 7.0 % targeted extrahepatic lesions. FFLP was evaluated in intrahepatic cases with a median follow-up of 19.5 months (interquartile range [IQR], 8.5-39.7). The 2-year FFLP exceeded 90 % across the treatment periods without significant differences (P = 0.51). According to the BCLC stages (0, A, B, and C), the 2-year FFLP rates were 95.5 %, 93.9 %, 98.5 %, and 87.6 %, respectively, and the 3-year FFLP rates were 91.1 %, 91.3 %, 95.0 %, and 83.3 %, respectively (P < 0.001). The median OS follow-up was 18.7 months (IQR 7.9-38.6). The 3-year OS rates were 81.1 % in BCLC stage 0; 65.5 %, stage A; 45.5 %, stage B; and 37.2 %, stage C, respectively (P < 0.001). CONCLUSION: This large, single-center study demonstrated that PBT provided favorable local control and survival outcomes, supporting its role as a promising local ablative modality to address the unmet therapeutic needs in HCC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lee JH, Kim N, Yu JI, et al. Tailored proton beam therapy for hepatocellular carcinoma: Addressing unmet needs through a multidisciplinary approach. Eur J Cancer. 2026. PMID: 41759412. doi:10.1016/j.ejca.2026.116593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。